Lege Artis Medicinae

[Scientific Digest]

MARCH 21, 2008

Lege Artis Medicinae - 2008;18(03)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Modern surgical treatment of lung cancer]

AGÓCS László

[Lung cancer is one of the most malignant human cancers because of its high incidence and high mortality rate. The 5-year relative survival rate for lung cancer at the initial diagnosis is 5-15%. Stage I or stage II non-small cell lung cancer (NSCLC) are considered early stage disease. Unfortunately, these two stages combined account for only 25 to 30% of tumours at the initial detection. At present, surgical resection remains the recommended treatment for patients with stage I and II NSCLC. Despite negative preoperative staging studies including mediastinoscopy, as many as one fourth of the patients will be found at surgery to have an occult N2 or one nodal station positive metastatic – stage IIIA – disease. Multimodality therapy is preferred for all subsets of stage IIIA patients. In stage IIIB and IV, surgical resection is possible and indicated only in selected cases, including Pancoast tumours, T4N0,1M0 tumours, the presence of satellite nodules in the same lobe, and certain solitary metastases. Patients with clinical stage T1-2 N0 small cell lung cancer (SCLC) may benefit from surgery for confirmation of diagnosis and improved local control when combined with chemotherapy. The mortality and morbidity rates of surgery in the treatment of lung cancer are reasonably low.]

Lege Artis Medicinae

[Umbilical hernia of extreme size in decompensated hepatic cirrhosis]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[Treatment of reflux-type symptoms - Guidelines of the College of Gastroenterology]

SIMON László

Lege Artis Medicinae

[Everyday Biostatistics Jenő Reiczigel, Andrea Harnos, Norbert Solymosi: Biostatistics for Non-Statistician]

dr. SINGER Júlia

Lege Artis Medicinae

[Points to consider in the treatment of viral hepatitis based on the most recent recommendations]

NEMESÁNSZKY Elemér

All articles in the issue

Related contents

Lege Artis Medicinae

[SCIENTIFIC DIGEST]

Hungarian Radiology

[Ceremonial scientific session on the occasion of Zoltán Dézsi’s 80th birthday - Debrecen, 10th November, 2008]

PINTYE Éva

Lege Artis Medicinae

[Considerations for the design and evaluation of qualitative research]

ZÖRGŐ Szilvia

[Communication, opinions, and experiences signify a vital part of medical knowledge and researching these realms necessitates qualitative methods. Scientific rigor is an equally valid expectation for qualitative research, and many facets have been proposed in related discourse. Aside from demonstrating the relevance and clinical application of a qualitative initiative, paying heed to its level of transferability is also crucial. The credibility and dependability of the project are pivotal, which can be enhanced through transparency, confirmability, and consistency in procedures employed during the processes of planning, implementation, and analysis. Furt­hermore, continual reflexivity denotes a chief aspect of scientific rigor throughout every phase of research, inviting the researcher to take a critical stance concerning their own preconceptions, as well as their effect on the topic under scrutiny. Apart from methodology, quantitative and qualitative worldview may be very different, for example in the way they treat and interpret reality. We may consider the various paradigms and methods as complementary in the quest of furthering medical knowledge. In this methodological spectrum, each element bears its own limitations and possibilities, thus in order to select the most adequate tool, these must be weighed in light of the research question and objectives.]

Lege Artis Medicinae

[Clinical trials for evaluating cardiovascular safety of SGLT-2- inhibitor drugs in patients with type 2 diabetes]

JERMENDY György

[SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs. ]

Hypertension and nephrology

[Scientific Program]